Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Chronic inflammatory skin diseases constitute a heterogeneous group of pathologies. They affect the skin but also other organs (joints, lungs, muscles, etc.). Their prognosis and response to treatments is extremely variable. The discovery of prognosis factors will help to precisely guide the treatment regimen and its intensification based on individual markers. The identification of new therapeutic targets is essential to develop new innovative treatments for inflammatory skin diseases.
The main objective is to identify new cellular or molecular prognostic factors associated with treatment response at 1 year in inflammatory skin diseases.
The secondary objectives are a better understanding of the pathophysiology of chronic inflammatory skin diseases, the identification of new cellular, molecular and microbiological prognostic factors associated with the clinical state after 10 years of evolution and the identification of prognostic markers of drug toxicity.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Patients | Affected by inflammatory skin disease |
| |
| Controls | Plastic surgery patients who have had any type of surgery resulting in healthy skin remnants |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Sampling | Other | Collection of an additional volume of blood, Superficial skin biopsy, Skin swab, Hair follicle, Stool, |
|
| Measure | Description | Time Frame |
|---|---|---|
| Therapeutic response | It is defined as complete or partial remission on the Investigator/Physician Global Assessment (IGA/PGA) scale. | At 1 year |
| Measure | Description | Time Frame |
|---|---|---|
| Expression of markers of blood and skin immunological signaling pathways | Mainly Th1, Th2, Th9, Th17, Th22 and Treg | At inclusion |
| Expression of markers of blood and skin immunological signaling pathways |
Not provided
Inclusion Criteria:
Patients:
Healthy controls :
Exclusion Criteria:
Not provided
Not provided
Not provided
Patients affected by inflammatory skin disease and controls
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Charles Cassius, MD | Contact | 630944832 | +33 | charles.cassius@aphp.fr |
| Jérôme Lambert, MD PhD | Contact | 142499742 | +33 | jerome.lambert@u-paris.fr |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hôpital Saint Louis | Recruiting | Paris | France |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Sampling | Other | Collection of an additional volume of blood, Preservation of post-operative skin remnants, Skin swab, Hair follicle, Stool |
|
Mainly Th1, Th2, Th9, Th17, Th22 and Treg
| At 4 months |
| Expression of markers of blood and skin immunological signaling pathways | Mainly Th1, Th2, Th9, Th17, Th22 and Treg | At 1 year |
| Expression of markers of blood T cell populations and skin transcriptomics | At inclusion |
| Expression of markers of blood T cell populations and skin transcriptomics | At 4 months |
| Expression of markers of blood T cell populations and skin transcriptomics | At 1 year |
| Therapeutic response | Based on markers of blood T cell populations and skin transcriptomics | At inclusion |
| Therapeutic response | Based on markers of blood T cell populations and skin transcriptomics | At 4 months |
| Therapeutic response | Based on markers of blood T cell populations and skin transcriptomics | At 1 year |
| Therapeutic response | Based on markers of blood T cell populations and skin transcriptomics | At 2 years |
| Therapeutic response | Based on markers of blood T cell populations and skin transcriptomics | At 3 years |
| Therapeutic response | Based on markers of blood T cell populations and skin transcriptomics | At 4 years |
| Therapeutic response | Based on markers of blood T cell populations and skin transcriptomics | At 5 years |
| Therapeutic response | Based on markers of blood T cell populations and skin transcriptomics | At 6 years |
| Therapeutic response | Based on markers of blood T cell populations and skin transcriptomics | At 7 years |
| Therapeutic response | Based on markers of blood T cell populations and skin transcriptomics | At 8 years |
| Therapeutic response | Based on markers of blood T cell populations and skin transcriptomics | At 9 years |
| Therapeutic response | Based on markers of blood T cell populations and skin transcriptomics | At 10 years |
| Microbiota markers | Identification of cluster specific to the pathology, identification of an over-representation of one or more microbiological species. For patients and controls | At inclusion |
| Microbiota markers | Identification of cluster specific to the pathology, identification of an over-representation of one or more microbiological species. For patients only | At 1 year |
| Proportion of patients suffering from adverse effects of systemic treatments | According to the CTCAE classification and MedDRA | At inclusion |
| Proportion of patients suffering from adverse effects of systemic treatments | According to the CTCAE classification and MedDRA | At 4 months |
| Proportion of patients suffering from adverse effects of systemic treatments | According to the CTCAE classification and MedDRA | At 1 year |
| Proportion of patients suffering from adverse effects of systemic treatments | According to the CTCAE classification and MedDRA | At 2 years |
| Proportion of patients suffering from adverse effects of systemic treatments | According to the CTCAE classification and MedDRA | At 3 years |
| Proportion of patients suffering from adverse effects of systemic treatments | According to the CTCAE classification and MedDRA | At 4 years |
| Proportion of patients suffering from adverse effects of systemic treatments | According to the CTCAE classification and MedDRA | At 5 years |
| Proportion of patients suffering from adverse effects of systemic treatments | According to the CTCAE classification and MedDRA | At 6 years |
| Proportion of patients suffering from adverse effects of systemic treatments | According to the CTCAE classification and MedDRA | At 7 years |
| Proportion of patients suffering from adverse effects of systemic treatments | According to the CTCAE classification and MedDRA | At 8 years |
| Proportion of patients suffering from adverse effects of systemic treatments | According to the CTCAE classification and MedDRA | At 9 years |
| Proportion of patients suffering from adverse effects of systemic treatments | According to the CTCAE classification and MedDRA | At 10 years |
| Quality of life measurement | The EPICES score (Evaluation of Deprivation and Inequalities in Health Examination Centers) is an individual measure of social deprivation. The score ranges from 0 to 100, where 0 indicates no deprivation and 100 indicates the highest level of deprivation. Higher EPICES scores reflect greater social deprivation and vulnerability. The Dermatology Life Quality Index (DLQI) is a dermatology-specific questionnaire used to assess the impact of skin disease on a patient's quality of life. The total score ranges from 0 to 30, with higher scores indicating greater impairment in quality of life. The SF-36 v1 is a generic health-related quality-of-life questionnaire that assesses eight domains of physical and mental health. Scores range from 0 to 100 for each domain, with higher scores indicating better health status and quality of life. | At inclusion |
| Quality of life measurement | The EPICES score (Evaluation of Deprivation and Inequalities in Health Examination Centers) is an individual measure of social deprivation. The score ranges from 0 to 100, where 0 indicates no deprivation and 100 indicates the highest level of deprivation. Higher EPICES scores reflect greater social deprivation and vulnerability. The Dermatology Life Quality Index (DLQI) is a dermatology-specific questionnaire used to assess the impact of skin disease on a patient's quality of life. The total score ranges from 0 to 30, with higher scores indicating greater impairment in quality of life. The SF-36 v1 is a generic health-related quality-of-life questionnaire that assesses eight domains of physical and mental health. Scores range from 0 to 100 for each domain, with higher scores indicating better health status and quality of life. | At 4 months |
| Quality of life measurement | The EPICES score (Evaluation of Deprivation and Inequalities in Health Examination Centers) is an individual measure of social deprivation. The score ranges from 0 to 100, where 0 indicates no deprivation and 100 indicates the highest level of deprivation. Higher EPICES scores reflect greater social deprivation and vulnerability. The Dermatology Life Quality Index (DLQI) is a dermatology-specific questionnaire used to assess the impact of skin disease on a patient's quality of life. The total score ranges from 0 to 30, with higher scores indicating greater impairment in quality of life. The SF-36 v1 is a generic health-related quality-of-life questionnaire that assesses eight domains of physical and mental health. Scores range from 0 to 100 for each domain, with higher scores indicating better health status and quality of life. | At 1 year |
| Quality of life measurement | The EPICES score (Evaluation of Deprivation and Inequalities in Health Examination Centers) is an individual measure of social deprivation. The score ranges from 0 to 100, where 0 indicates no deprivation and 100 indicates the highest level of deprivation. Higher EPICES scores reflect greater social deprivation and vulnerability. The Dermatology Life Quality Index (DLQI) is a dermatology-specific questionnaire used to assess the impact of skin disease on a patient's quality of life. The total score ranges from 0 to 30, with higher scores indicating greater impairment in quality of life. The SF-36 v1 is a generic health-related quality-of-life questionnaire that assesses eight domains of physical and mental health. Scores range from 0 to 100 for each domain, with higher scores indicating better health status and quality of life. | At 2 years |
| Quality of life measurement | The EPICES score (Evaluation of Deprivation and Inequalities in Health Examination Centers) is an individual measure of social deprivation. The score ranges from 0 to 100, where 0 indicates no deprivation and 100 indicates the highest level of deprivation. Higher EPICES scores reflect greater social deprivation and vulnerability. The Dermatology Life Quality Index (DLQI) is a dermatology-specific questionnaire used to assess the impact of skin disease on a patient's quality of life. The total score ranges from 0 to 30, with higher scores indicating greater impairment in quality of life. The SF-36 v1 is a generic health-related quality-of-life questionnaire that assesses eight domains of physical and mental health. Scores range from 0 to 100 for each domain, with higher scores indicating better health status and quality of life. | At 3 years |
| Quality of life measurement | The EPICES score (Evaluation of Deprivation and Inequalities in Health Examination Centers) is an individual measure of social deprivation. The score ranges from 0 to 100, where 0 indicates no deprivation and 100 indicates the highest level of deprivation. Higher EPICES scores reflect greater social deprivation and vulnerability. The Dermatology Life Quality Index (DLQI) is a dermatology-specific questionnaire used to assess the impact of skin disease on a patient's quality of life. The total score ranges from 0 to 30, with higher scores indicating greater impairment in quality of life. The SF-36 v1 is a generic health-related quality-of-life questionnaire that assesses eight domains of physical and mental health. Scores range from 0 to 100 for each domain, with higher scores indicating better health status and quality of life. | At 4 years |
| Quality of life measurement | The EPICES score (Evaluation of Deprivation and Inequalities in Health Examination Centers) is an individual measure of social deprivation. The score ranges from 0 to 100, where 0 indicates no deprivation and 100 indicates the highest level of deprivation. Higher EPICES scores reflect greater social deprivation and vulnerability. The Dermatology Life Quality Index (DLQI) is a dermatology-specific questionnaire used to assess the impact of skin disease on a patient's quality of life. The total score ranges from 0 to 30, with higher scores indicating greater impairment in quality of life. The SF-36 v1 is a generic health-related quality-of-life questionnaire that assesses eight domains of physical and mental health. Scores range from 0 to 100 for each domain, with higher scores indicating better health status and quality of life. | At 5 years |
| Quality of life measurement | The EPICES score (Evaluation of Deprivation and Inequalities in Health Examination Centers) is an individual measure of social deprivation. The score ranges from 0 to 100, where 0 indicates no deprivation and 100 indicates the highest level of deprivation. Higher EPICES scores reflect greater social deprivation and vulnerability. The Dermatology Life Quality Index (DLQI) is a dermatology-specific questionnaire used to assess the impact of skin disease on a patient's quality of life. The total score ranges from 0 to 30, with higher scores indicating greater impairment in quality of life. The SF-36 v1 is a generic health-related quality-of-life questionnaire that assesses eight domains of physical and mental health. Scores range from 0 to 100 for each domain, with higher scores indicating better health status and quality of life. | At 6 years |
| Quality of life measurement | The EPICES score (Evaluation of Deprivation and Inequalities in Health Examination Centers) is an individual measure of social deprivation. The score ranges from 0 to 100, where 0 indicates no deprivation and 100 indicates the highest level of deprivation. Higher EPICES scores reflect greater social deprivation and vulnerability. The Dermatology Life Quality Index (DLQI) is a dermatology-specific questionnaire used to assess the impact of skin disease on a patient's quality of life. The total score ranges from 0 to 30, with higher scores indicating greater impairment in quality of life. The SF-36 v1 is a generic health-related quality-of-life questionnaire that assesses eight domains of physical and mental health. Scores range from 0 to 100 for each domain, with higher scores indicating better health status and quality of life. | At 7 years |
| Quality of life measurement | The EPICES score (Evaluation of Deprivation and Inequalities in Health Examination Centers) is an individual measure of social deprivation. The score ranges from 0 to 100, where 0 indicates no deprivation and 100 indicates the highest level of deprivation. Higher EPICES scores reflect greater social deprivation and vulnerability. The Dermatology Life Quality Index (DLQI) is a dermatology-specific questionnaire used to assess the impact of skin disease on a patient's quality of life. The total score ranges from 0 to 30, with higher scores indicating greater impairment in quality of life. The SF-36 v1 is a generic health-related quality-of-life questionnaire that assesses eight domains of physical and mental health. Scores range from 0 to 100 for each domain, with higher scores indicating better health status and quality of life. | At 8 years |
| Quality of life measurement | The EPICES score (Evaluation of Deprivation and Inequalities in Health Examination Centers) is an individual measure of social deprivation. The score ranges from 0 to 100, where 0 indicates no deprivation and 100 indicates the highest level of deprivation. Higher EPICES scores reflect greater social deprivation and vulnerability. The Dermatology Life Quality Index (DLQI) is a dermatology-specific questionnaire used to assess the impact of skin disease on a patient's quality of life. The total score ranges from 0 to 30, with higher scores indicating greater impairment in quality of life. The SF-36 v1 is a generic health-related quality-of-life questionnaire that assesses eight domains of physical and mental health. Scores range from 0 to 100 for each domain, with higher scores indicating better health status and quality of life. | At 9 years |
| Quality of life measurement | The EPICES score (Evaluation of Deprivation and Inequalities in Health Examination Centers) is an individual measure of social deprivation. The score ranges from 0 to 100, where 0 indicates no deprivation and 100 indicates the highest level of deprivation. Higher EPICES scores reflect greater social deprivation and vulnerability. The Dermatology Life Quality Index (DLQI) is a dermatology-specific questionnaire used to assess the impact of skin disease on a patient's quality of life. The total score ranges from 0 to 30, with higher scores indicating greater impairment in quality of life. The SF-36 v1 is a generic health-related quality-of-life questionnaire that assesses eight domains of physical and mental health. Scores range from 0 to 100 for each domain, with higher scores indicating better health status and quality of life. | At 10 years |
| ID | Term |
|---|---|
| D003876 | Dermatitis, Atopic |
| D011565 | Psoriasis |
| D017497 | Hidradenitis Suppurativa |
| D008010 | Lichen Planus |
| D003882 | Dermatomyositis |
| D017445 | Skin Diseases, Vascular |
| ID | Term |
|---|---|
| D012873 | Skin Diseases, Genetic |
| D030342 | Genetic Diseases, Inborn |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
| D003872 | Dermatitis |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |
| D017443 | Skin Diseases, Eczematous |
| D006969 | Hypersensitivity, Immediate |
| D006967 | Hypersensitivity |
| D007154 | Immune System Diseases |
| D017444 | Skin Diseases, Papulosquamous |
| D017192 | Skin Diseases, Bacterial |
| D001424 | Bacterial Infections |
| D001423 | Bacterial Infections and Mycoses |
| D007239 | Infections |
| D012874 | Skin Diseases, Infectious |
| D013492 | Suppuration |
| D016575 | Hidradenitis |
| D013543 | Sweat Gland Diseases |
| D017512 | Lichenoid Eruptions |
| D017285 | Polymyositis |
| D009220 | Myositis |
| D009135 | Muscular Diseases |
| D009140 | Musculoskeletal Diseases |
| D009468 | Neuromuscular Diseases |
| D009422 | Nervous System Diseases |
| D003240 | Connective Tissue Diseases |
Not provided
Not provided